ES2152986T3 - Genoterapia de celulas mesoteliales. - Google Patents

Genoterapia de celulas mesoteliales.

Info

Publication number
ES2152986T3
ES2152986T3 ES94920753T ES94920753T ES2152986T3 ES 2152986 T3 ES2152986 T3 ES 2152986T3 ES 94920753 T ES94920753 T ES 94920753T ES 94920753 T ES94920753 T ES 94920753T ES 2152986 T3 ES2152986 T3 ES 2152986T3
Authority
ES
Spain
Prior art keywords
cells
expression system
mesothelial
mesotelial
genotherapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94920753T
Other languages
English (en)
Inventor
Ty Robert Shockley
Robert William Jackman
Janice Ann Nagy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beth Israel Deaconess Medical Center Inc
Original Assignee
Beth Israel Hospital Association
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beth Israel Hospital Association filed Critical Beth Israel Hospital Association
Application granted granted Critical
Publication of ES2152986T3 publication Critical patent/ES2152986T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0688—Cells from the lungs or the respiratory tract
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

METODOS Y COMPOSICIONES FARMACEUTICAS PARA MODIFICAR LAS CELULAS MESOTELIALES DE UN RECIPIENTE MAMIFERO IN SITU. LOS METODOS INCLUYEN LA FORMACION DE UN SISTEMA DE EXPRESION DE CELULA MESOTELIAL IN VIVO O EX VIVO Y LA ADMINISTRACION DEL SISTEMA DE EXPRESION AL RECIPIENTE MAMIFERO (MEDIANTE LAS CAVIDADES CORPORALES NORMALMENTE RECUBIERTAS POR LAS CELULAS MESOTELIALES). EL SISTEMA DE EXPRESION DE CELULA MESOTELIAL ES UTIL PARA EL ENVIO LOCALIZADO Y SISTEMICO DE AGENTES TERAPEUTICOS IN SITU.
ES94920753T 1993-06-18 1994-06-15 Genoterapia de celulas mesoteliales. Expired - Lifetime ES2152986T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/080,474 US5645829A (en) 1993-06-18 1993-06-18 Mesothelial cell gene therapy

Publications (1)

Publication Number Publication Date
ES2152986T3 true ES2152986T3 (es) 2001-02-16

Family

ID=22157605

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94920753T Expired - Lifetime ES2152986T3 (es) 1993-06-18 1994-06-15 Genoterapia de celulas mesoteliales.

Country Status (9)

Country Link
US (2) US5645829A (es)
EP (2) EP1024197A3 (es)
JP (1) JP3466194B2 (es)
AT (1) ATE197719T1 (es)
AU (1) AU688342B2 (es)
CA (1) CA2164424A1 (es)
DE (1) DE69426328T2 (es)
ES (1) ES2152986T3 (es)
WO (1) WO1995000654A1 (es)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5645829A (en) * 1993-06-18 1997-07-08 Beth Israel Hospital Association Mesothelial cell gene therapy
AU3518695A (en) * 1994-08-26 1996-03-22 Beth Israel Deaconess Medical Center Gene therapy for transplantation and inflammatory or thrmbotic conditions
US5704910A (en) 1995-06-05 1998-01-06 Nephros Therapeutics, Inc. Implantable device and use therefor
DK0970206T3 (da) 1997-01-27 2008-10-13 Ludwig Inst Cancer Res Lage-1-tumorassocierede nukleinsyrer
CA2205076A1 (en) 1997-05-14 1998-11-14 Jim Hu Episomal expression cassettes for gene therapy
US6548296B1 (en) 1997-07-23 2003-04-15 Roche Diagnostics Gmbh Methods for identifying human cell lines useful for endogenous gene activation, isolated human lines identified thereby, and uses thereof
WO1999008533A1 (en) * 1997-08-13 1999-02-25 Yale University Central nervous system axon regeneration
US20080233098A1 (en) * 1997-10-31 2008-09-25 Mckerracher Lisa RHO Family Antagonists and Their Use to Block Inhibition of Neurite Outgrowth
US20030118567A1 (en) * 1999-03-26 2003-06-26 Stewart Duncan John Cell-based therapy for the pulmonary system
US7169783B2 (en) * 1998-11-02 2007-01-30 Universite De Montreal (+)-Trans-4-(1-aminoethyl)-1-(4-pyridycarbamoyl)-cyclohexane and method for promoting neural growth in the central nervous system and in a patient at a site of neuronal lesion
US7063959B1 (en) 1998-12-30 2006-06-20 Beth Israel Deaconess Medical Center, Inc. Compositions of the SOC/CRAC calcium channel protein family
CA2360396A1 (en) 1998-12-30 2000-07-13 Andrew M. Scharenberg Characterization of a calcium channel family
US7166573B1 (en) 1999-05-28 2007-01-23 Ludwig Institute For Cancer Research Breast, gastric and prostate cancer associated antigens and uses therefor
US6696272B1 (en) 1999-06-02 2004-02-24 Hsc Research & Development Limited Partnership Products and methods for gaucher disease therapy
ES2592507T3 (es) 1999-09-03 2016-11-30 The Brigham And Women's Hospital, Inc. Métodos y composiciones para el tratamiento de enfermedad inflamatoria mediante el uso de agentes moduladores de cadherina-11
US20020142299A1 (en) * 2001-01-09 2002-10-03 Davidson Beverly L. PTD-modified proteins
US7794707B2 (en) * 2002-06-19 2010-09-14 University Health Network ACE2 activation for treatment of heart, lung and kidney disease and hypertension
NZ596420A (en) 2003-02-11 2012-11-30 Shire Human Genetic Therapies Diagnosis and treatment of multiple sulfatase deficiency and other sulfatase deficiencies
EP1484410B1 (en) * 2003-06-05 2011-11-02 Ajinomoto Co., Inc. Fermentation methods using modified bacteria with increased byproduct uptake.
AU2005285483A1 (en) * 2004-08-05 2006-03-23 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for cell activation
EP1824529B1 (en) * 2004-12-08 2010-07-21 Pervasis Therapeutics, Inc. Compositions and their use for enhancing vascular access
CA2605080A1 (en) * 2005-04-21 2006-11-02 Massachusetts Institute Of Technology Materials and methods for altering an immune response to exogenous and endogenous immunogens, including syngeneic and non-syngeneic cells, tissues or organs
WO2007001744A2 (en) * 2005-06-21 2007-01-04 Pervasis Therapeutics, Inc. Methods and compositions for enhancing vascular access
US20100204783A1 (en) * 2005-12-06 2010-08-12 Helen Marie Nugent Methods and compositions for enhancing vascular access
US20090068158A1 (en) * 2005-12-09 2009-03-12 Medin Jeffrey A Thymidylate kinase mutants and uses thereof
US20090074733A1 (en) * 2005-12-09 2009-03-19 Medin Jeffrey A Thymidylate kinase mutants and uses thereof
EP2514824A3 (en) 2006-03-03 2013-01-23 Amorfix Life Sciences Ltd. Methods and compositions to treat and detect misfolded-SOD1 mediated diseases
EP2079478A2 (en) * 2006-11-07 2009-07-22 Pervasis Therapeutics, Inc. Materials and methods for treating and managing angiogenesis-mediated diseases
CA2584494A1 (en) * 2007-03-27 2008-09-27 Jeffrey A. Medin Vector encoding therapeutic polypeptide and safety elements to clear transduced cells
WO2009014565A2 (en) 2007-04-26 2009-01-29 Ludwig Institute For Cancer Research, Ltd. Methods for diagnosing and treating astrocytomas
EP2150618B1 (en) 2007-05-04 2017-10-11 University Health Network Il-12 immunotherapy for cancer
ES2381641T3 (es) * 2007-06-13 2012-05-30 Pervasis Therapeutics, Inc. Métodos y dispositivos para la administración mínimamente invasiva de composiciones fluidas que contienen células
EP2077119A1 (de) * 2007-12-21 2009-07-08 Apeiron Biologics Forschungs- und Entwicklungsgesellschaft M.B.H. Behandlung von Fibrosen und Lebererkrankungen
JP2011513399A (ja) 2008-03-03 2011-04-28 ザ ユニバーシティー オブ マイアミ 同種癌細胞による免疫療法
WO2009117116A2 (en) 2008-03-20 2009-09-24 University Of Miami Heat shock protein gp96 vaccination and methods of using same
WO2009114942A1 (en) 2008-03-20 2009-09-24 University Health Network Thymidylate kinase fusions and uses thereof
EP2113261B1 (en) 2008-04-29 2013-11-06 Proxy Biomedical Limited A Tissue Repair Implant
CA2728215A1 (en) 2008-06-18 2010-06-24 Innovative Biotherapies, Inc. Methods for enhanced propagation of cells
CN102802658A (zh) 2009-12-21 2012-11-28 台湾东洋药品工业股份有限公司 白细胞衍生趋化因子2于肿瘤细胞内降低肝细胞生长因子受体的磷酸化相关的方法与组合物
KR20190000385A (ko) 2010-05-04 2019-01-02 더 브리검 앤드 우먼즈 하스피털, 인크. 섬유증의 검출 및 치료
WO2014074785A1 (en) 2012-11-08 2014-05-15 Ludwig Institute For Cancer Research Ltd. Methods of predicting outcome and treating breast cancer
CN105051204B (zh) 2012-11-16 2023-07-21 波赛伊达治疗学股份有限公司 位点特异性酶和使用方法
US20160263186A1 (en) * 2013-10-22 2016-09-15 Bioincept, Llc Pif-transfected cells and methods of use
RU2553342C1 (ru) * 2014-04-18 2015-06-10 Государственное бюджетное образовательное учреждение высшего профессионального образования Первый Московский государственный медицинский университет им. И.М. Сеченова Министерства здравоохранения Российской Федерации (ГБОУ ВПО Первый МГМУ им. И.М. Сеченова Минздрава России) Способ лечения инфекционного перитонита в эксперименте
PT3310909T (pt) 2015-06-17 2021-09-09 Poseida Therapeutics Inc Composições e métodos para dirigir proteínas para loci específicos no genoma
US11090355B2 (en) 2015-08-28 2021-08-17 Bioincept, Llc Compositions and methods for the treatment of neurodamage
US11096987B2 (en) 2015-08-28 2021-08-24 Bioincept, Llc Mutant peptides and methods of treating subjects using the same
WO2019126578A1 (en) 2017-12-20 2019-06-27 Poseida Therapeutics, Inc. Compositions and methods for directing proteins to specific loci in the genome

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4755593A (en) * 1985-07-24 1988-07-05 Lauren Mark D Novel biomaterial of cross-linked peritoneal tissue
US4885238A (en) * 1987-10-30 1989-12-05 The United States Of America As Represented By The Department Of Health And Human Services Immortalized human bronchial epitherial mesothelial cell lines
US5443954A (en) * 1987-10-30 1995-08-22 The United States Of America As Represented By The Department Of Health And Human Services Immortalized non-tumorigenic human bronchial epithelial cell lines
WO1990006997A1 (en) * 1988-12-13 1990-06-28 United States Government As Represented By The Secretary Of The Department Of Health And Human Services Genetically engineered endothelial cells and use thereof
US5399346A (en) * 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
CA2044593C (en) * 1989-11-03 2004-04-20 Kenneth L. Brigham Method of in vivo delivery of functioning foreign genes
DE4001319A1 (de) * 1990-01-18 1991-07-25 Jakob Dr Bodziony Ein implantierbares und biologisch aktive substanzen sezernierendes bioartifizielles organ
DE4011100A1 (de) * 1990-01-18 1991-10-10 Jakob Dr Bodziony Ein extrakorporales oder ein implantierbares bio-artifizielles organ, welches verschiedene organfunktionen ersetzen oder unterstuetzen kann
US5279833A (en) * 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
IE20010427A1 (en) * 1990-04-10 2003-03-05 Canji Inc Gene therapy for cell proliferative diseases
DE4123629A1 (de) * 1990-08-06 1992-02-20 Jakob Dr Bodziony Ein implantierbares und biologisch aktive substanzen sezernierendes bio-artifizielles organ, das auf dem prinzip des druckgradients funktioniert
ES2080341T3 (es) * 1990-09-14 1996-02-01 Univ Johns Hopkins Metodos y composiciones para la terapia genetica y la potenciacion de la inmunidad antitumoral.
WO1992006180A1 (en) * 1990-10-01 1992-04-16 University Of Connecticut Targeting viruses and cells for selective internalization by cells
EP0563239A4 (en) * 1990-12-20 1994-10-12 Univ Pittsburgh A truncated interleukin-1 receptor gene for the treatment of arthritis.
WO1992015676A1 (en) * 1991-03-08 1992-09-17 The Salk Institute For Biological Studies Somatic cell gene therapy
EP0648271B1 (en) * 1991-08-20 2003-04-16 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Adenovirus mediated transfer of genes to the gastrointestinal tract
US5645829A (en) * 1993-06-18 1997-07-08 Beth Israel Hospital Association Mesothelial cell gene therapy
US5797870A (en) * 1995-06-07 1998-08-25 Indiana University Foundation Pericardial delivery of therapeutic and diagnostic agents

Also Published As

Publication number Publication date
ATE197719T1 (de) 2000-12-15
CA2164424A1 (en) 1995-01-05
EP0703988A1 (en) 1996-04-03
WO1995000654A1 (en) 1995-01-05
EP1024197A3 (en) 2005-11-23
US6068837A (en) 2000-05-30
JP3466194B2 (ja) 2003-11-10
DE69426328D1 (de) 2000-12-28
AU7174194A (en) 1995-01-17
US5645829A (en) 1997-07-08
EP1024197A2 (en) 2000-08-02
JPH09501048A (ja) 1997-02-04
EP0703988B1 (en) 2000-11-22
DE69426328T2 (de) 2002-05-29
AU688342B2 (en) 1998-03-12

Similar Documents

Publication Publication Date Title
ES2152986T3 (es) Genoterapia de celulas mesoteliales.
DE69213744D1 (de) Verabreichung von antisensen oligonukleotiden und peptiden als arzeneimittel an geweben in vivo und an zellen durch verwendung von avidin-biotin-technologie
LV10180A (lv) Farmaceitiska kompozicija
NZ236823A (en) Topical pharmaceutical and cosmetic compositions containing a salt of cholanic acid, a lipid and optionally a pharmaceutically or cosmetically active substance
ATE136792T1 (de) Zellmembran-mischungsmittel enthaltende molekularkonjugate
DE69921138D1 (de) Arzneimittel freisetzendes system enthaltend ein homeobox-peptid und ein zytotoxisches oder antineoplastisches mittel
ATE81986T1 (de) Wirkstoff - monoklonale antikoerper - konjugate.
FI963103A0 (fi) Ei-virusvektori
DK1125577T3 (da) Væskeformige medikamentindföringspræparater
FI963424A (fi) Menetelmä terapeuttisesti aktiivisten tiofeenisulfonamidien valmistamiseksi
DE69133623D1 (de) Haltende neue pharmazeutische formulierungen sowie verfahren zu deren herstellung
AU6628496A (en) Polyether block copolymer micellar compositions for targeting biological agents
DE69812727D1 (de) Opioid-konjugate mit endogenen Trägerproteinen
HUP9800731A2 (hu) Eljárás ivarsejt osztódás stimulálására
ES2168457T3 (es) Composiciones farmaceuticas que comprenden una superoxido dismutasa.
FR2730411B1 (fr) Association medicamenteuse utile pour la transfection et l'expression in vivo d'exogenes
IL134593A0 (en) A cell system for in-vivo expression of an interferon beta protein, pharmaceutical compositions containing the same and methods for the preparation thereof
GR3017855T3 (en) Use of lithium in the treatment or prophylaxis of Molluscum contagiosum.
DK1004320T3 (da) Anvendelse af magnesium (Mg2+) til forbedring af genadministration ved genterapi
BR9810458A (pt) Solução, composição farmacêutica, e, cápsula de gelatina carregada lìquida
MX9700560A (es) Metodo de uso de integrasa retroviral negativa transdominante en el tratamiento de infecciones retrovirales.
ATE499115T1 (de) Antikörper verwiesene enzymprodrugtherapie mit glukuronidase
WO1998036778A8 (en) Sustained drug delivery and compositions useful therefor
FR2622445B1 (fr) Application de groupes nitrophenyles a la stimulation des capacites d'incorporation d'un medicament dans les cellules sensibles de l'hote
RU93018896A (ru) Способ прогнозирования эффективности психофармакотерапии эндогенных психозов

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 703988

Country of ref document: ES